Heparin anticoagulation followed by protamine reversal is commonly used in cardiopulmonary bypass (CPB). As an alternative to protamine, a recombinant inactive antithrombin (riAT) was designed as an antidote to heparin and was previously shown to be as potent as protamine in-vitro. In the present study, riAT was assessed for its ability to neutralize heparin after CPB in a rat model. After 60 min of CPB under heparin, rats received 5 mg/kg protamine, 37.5 mg/kg riAT or phosphate buffered saline (PBS) as placebo. Residual anticoagulant activity was assessed using the activated partial thromboplastin time assay before, and 10-30 min after reversion. Haemodynamic monitoring was performed and plasma histamine concentration was also measured. In this model, riAT appeared to be as efficient as protamine in neutralizing heparin. Ten minutes after injection, riAT and protamine both decreased heparin activity, to 1.8 AE 1.3 and 4.5 AE 1.4 u/ ml, respectively (23.1 AE 5.1 u/ml in placebo group). Furthermore, evolution of mean carotid arterial pressure, heart rate and plasma histamine levels was comparable in rats treated with PBS or riAT, while protamine exhibited haemodynamic side effects and increased histamine plasma concentration. Thus, riAT could represent an advantage over protamine in CPB because it efficiently reverses heparin activity without negative effects on haemodynamic parameters and plasma histamine level.
Summary
Heparin anticoagulation followed by protamine reversal is commonly used in cardiopulmonary bypass (CPB) . As an alternative to protamine, a recombinant inactive antithrombin (riAT) was designed as an antidote to heparin and was previously shown to be as potent as protamine in-vitro. In the present study, riAT was assessed for its ability to neutralize heparin after CPB in a rat model. After 60 min of CPB under heparin, rats received 5 mg/kg protamine, 37.5 mg/kg riAT or phosphate buffered saline (PBS) as placebo. Residual anticoagulant activity was assessed using the activated partial thromboplastin time assay before, and 10-30 min after reversion. Haemodynamic monitoring was performed and plasma histamine concentration was also measured. In this model, riAT appeared to be as efficient as protamine in neutralizing heparin. Ten minutes after injection, riAT and protamine both decreased heparin activity, to 1.8 AE 1.3 and 4.5 AE 1.4 u/ ml, respectively (23.1 AE 5.1 u/ml in placebo group). Furthermore, evolution of mean carotid arterial pressure, heart rate and plasma histamine levels was comparable in rats treated with PBS or riAT, while protamine exhibited haemodynamic side effects and increased histamine plasma concentration. Thus, riAT could represent an advantage over protamine in CPB because it efficiently reverses heparin activity without negative effects on haemodynamic parameters and plasma histamine level.
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Unfractionated heparin (UFH) remains the anticoagulant of choice during extracorporeal circulation because of its short half-life, ease of monitoring and availability of a reversal agent. Indeed, protamine sulfate rapidly and efficiently neutralizes heparin anticoagulant activity after extracorporeal circulation, but its use carries some severe adverse events. Protamine-associated events, such as systemic hypotension, anaphylactic reaction or pulmonary vasoconstriction, occur rarely but are often life threatening (Horrow, 1985) .
Protamine is also known to be immunogenic (Bakchoul et al, 2013) . Furthermore, protamine exerts counterproductive anticoagulant activity by inhibiting activation of the tissue factor pathway (Chu et al, 2001 ) and factor V (Ni Ainle et al, 2009) and requires accurate dose adjustment relative to heparin concentration (Hirsh et al, 2008) . Because of these major complications, many safer alternatives to heparin/protamine combination have been proposed but none of them have been approved for anticoagulant/antidote use in cardiopulmonary bypass (CPB) procedures (Cushing et al, 2010; Olson et al, 2012; Lu et al, 2013; Shenoi et al, 2014; Ansell et al, 2016; Kalaska et al, 2016) .
Previously, our group designed a recombinant antithrombin (AT) that was devoid of anticoagulant activity but which retained its ability to tightly bind heparin (Bianchini et al, 2011) . Recombinant inactive AT (riAT) was obtained by inserting a proline between the arginine393 and serine394 residues within the reactive centre loop, and by replacing asparagine135 with a glutamine residue. These two mutations result in a loss of AT inhibitory activity and a gain of its affinity for heparin. This riAT acts as specific and efficient antidote to heparin by a competition mechanism with native plasma AT. In previous studies, riAT potently neutralized the anticoagulant activity of AT-dependent anticoagulants, such as fondaparinux, low molecular weight heparin (LMWH), and UFH. In ex-vivo studies, when added to human plasma overloaded with heparin, riAT dose-dependently inhibited anti-factor Xa or anti-factor IIa activities (Bianchini et al, 2011) . It also appears to be as effective as protamine in reversing heparin anticoagulant activity when assessed in a global coagulation assay, such as the thrombin generation assay (Bourti et al, 2016) . In an in-vivo study, intra-venous injection of riAT considerably decreased anti-factor Xa activity in the plasma of mice treated with high dose fondaparinux (Bianchini et al, 2011) . Considering these results, riAT appears to be a good candidate to neutralize the anticoagulant effects of heparin during CPB.
To test whether riAT may replace protamine to reverse heparin anticoagulant activity after extracorporeal circulation, we used a rat model of CPB using UFH as anticoagulant (Lebreton et al, 2012) . This model was set up to explore anticoagulant reversion after CPB procedure.
Materials and methods

Materials
Large-scale production of riAT was performed using the FreeStyle TM 293 Expression System as recommended by the manufacturer (Invitrogen, Thermo Fisher, Villebon s/Yvette, France). riAT was further purified from clarified serum-free cell culture supernatant by a combination of chromatographies as previously described and recovered with PBS, pH 7.4 (Invitrogen) (Bianchini et al, 2011) .
Animals
Male Wistar rats (Janvier, Le Genest-Saint-Isle, France) weighing 300-350 g were used in all the experiments. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the French "Minist ere de l'Enseignement Sup erieur et de la Recherche -Direction G en erale pour la Recherche et l'Innovation".
Cardiopulmonary bypass procedure
All surgical procedures were performed under aseptic conditions and the sterilized materials were used once only. Animals were anesthetized with intraperitoneal administration of ketamine (100 mg/kg) and xylazine chlorhydrate (10 mg/kg), and intra-arterial reinjections of ketamine (12.5 mg/kg) were used every 15 min. Once anaesthesia was achieved, the animals were placed in a supine position on a heating plate, and a rectal probe was used to monitor their temperature, ranging from 35 to 37°C. Animals were ventilated through a 16G tracheal tube with the 7025 Rodent Ventilator â (Ugo Basile, Gemonio, Italy), of which the respiratory parameters were: tidal volume, 10 ml/kg; rate, 75 cycles/min and 100% FiO 2 . Invasive arterial blood pressure was monitored on the left carotid artery through a 22 G catheter with the PowerLab â device (AD Instruments, Paris, France). Mean arterial pressure (MAP) was maintained at 70 mmHg during CPB and 60 mmHg post-CPB, using an injection of 0.5 ml of Gelofusine 4% if necessary.
A partial femorofemoral CPB, with a 16 G catheter in the femoral vein and a 22 G catheter in the femoral artery, was performed in all animals, employing a previously described surgical technique (Lebreton et al, 2012) , with the Micro-1 Rat Oxygenator â (Kewei Inc., Shenzhen, China). The extracorporeal circuit was primed with 10 ml of Gelofusine 4%. The anticoagulation protocol during CPB consisted of two injections of 500 iu/kg heparin sodium (heparin sodium â , Panpharma, Luitr e, France), one at 5 min before initiation of CPB, and one at 30 min after initiation of CPB. The dose of heparin sodium was chosen to avoid any coagulation in the lines or in the oxygenator during the CPB procedure. No signs of thrombosis were observed at 500 iu/kg. CPB lasted for 60 min, after which the extracorporeal circuit was removed, but the cannulas remained in the femoral vessels. Antidotes (0.5-0.6 ml) were then infused for 5 min via the femoral vein cannula. Animals were divided into three different groups: (i) Group 1 (protamine group; n = 10) received protamine sulfate (Choay â , Sanofi, Gentilly. France) at the dose of 5 mg/kg, (ii) Group 2 (riAT group, n = 6) received riAT at the dose of 37.5 mg/kg, (iii) and Group 3 (PBS group, n = 10) received PBS as placebo. The dose of protamine was chosen according to its anti-heparin activity (1 mg protamine neutralizes 100 iu UFH), whereas the dose of riAT was chosen based on previous in-vitro experiments, indicating that neutralization of UFH required a minimal concentration of 0.9 mg/ml riAT extemporaneously spiked in the plasma of rats treated with the same anticoagulation and CPB procedure, and by assuming a plasma volume of approximately 40 ml/kg in rats (Gillen CM et al p. 485) and a bioavailability of 100% when administered intravenously.
Post-CPB monitoring lasted 60 min, after which all the animals were euthanized.
Haemodynamic parameters measurement
A catheter in the left carotid allowed continuous monitoring of arterial pressure with the PowerLab â device (AD Instrument). Carotid MAP and heart rate (HR) were collected using LabChart Reader â (AD Instrument).
Plasma coagulation assay
Citrated blood samples (9:1 v/v of blood/3.2% sodium citrate) were withdrawn through the carotid catheter at the end of CPB, before antidote administration, and then 10 and 30 min after antidote infusion. Samples were immediately centrifuged twice at 3000 g for 10 min and plasma was stored at À80°C. Heparin anticoagulant activity was evaluated by measuring prolongation of the activated Partial Thromboplastin Time (aPTT) in rat plasma using hemosIL APTT-SP reagents (Instrumentation Laboratory, Bedford, MA, USA) on a STart â 4 Haemostasis Analyser (Stago, Asni eres-sur-Seine, France). Plasma samples were diluted in a pool of naive rat plasma and heparin concentration was calculated using a standard curve established by spiking heparin in this pool using the same lot of reagents.
Plasma histamine concentration
Heparinized blood samples (24:1 v/v of blood/5000 u/ml heparin) were withdrawn through the carotid catheter at the end of CPB, before antidote administration and 60 min after antidote infusion. Samples were immediately centrifuged twice at 3000 g for 10 min and plasma was stored at À80°C. Plasma histamine concentration was measured using Histamine ELISA Kit â BA-E-1000 (ImmuSmol, Pessac, France) following the manufacturer's instructions.
Statistical analysis
Values are expressed as mean AE standard error of means. Mean values of each group were compared by one-way analysis of variance (ANOVA) followed by a Fisher's test using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA), with P < 0.05 considered to be statistically significant.
Results
Efficacy of riAT for heparin reversal in a rat model of extracorporeal circulation
To test whether riAT could safely replace protamine as heparin reversal in CPB, riAT was assessed in a rat model of CPB and compared to protamine. To prevent blood clotting in extracorporeal circulation circuits, rats were treated with heparin before the CPB procedure, and heparin treatment was repeated 30 min after initiation of CPB to maintain a high heparin concentration in rat plasma during the entire CPB procedure. After 60 min, extracorporeal circulation was interrupted and residual heparin concentration was measured in rat plasma using an aPTT assay. As expected, before antidote administration, plasma heparin concentration was elevated and comparable in each group of rats: 111.9 AE 49.5 u/ ml in the Protamine group, 141.4 AE 45.3 u/ml in the rats riAT group and 96.7 AE 29.9 u/ml in the PBS group (Fig 1) . However, 10 min after antidote perfusion, both protamine and riAT exhibited potent antidote activities, as evidenced by significant decreases of heparin activity in plasma of rats treated with protamine (4.5 AE 1.4 u/ml, P = 0.0006) or riAT (1.8 AE 0.6 u/ml, P = 0.0007), compared to rats treated with PBS as placebo (23.1 AE 5.1 u/ml). Although non-significant, mean plasma heparin concentrations in rats treated with riAT were systematically lower than those measured in rats treated with protamine, suggesting that, at the doses tested, riAT could be slightly more effective than protamine in reversing heparin anticoagulant activity. In the group of rats treated with PBS, plasma heparin activity decreased as a function of time, from an elevated anticoagulant activity right after CPB procedure (96.7 AE 29.9 u/ml) to a lower residual activity 30 min after CPB (12.7 AE 4.8 u/ml), due to Plasma heparin concentration during cardiopulmonary bypass (CPB). All rats underwent 60 min CPB after an initial heparin administration (500 iu/kg), renewed in the midterm of CPB. Residual heparin activity was obtained by measuring prolongation of the activated partial thromboplastin time, at the end of CPB, and at 10 and 30 min after reversal infusion, in the plasma of rats treated with phosphate-buffered saline (PBS) as placebo (n = 10, black bars), 5 mg/kg protamine (n = 10, grey bars) or 37.5 mg/kg recombinant inactive antithrombin (riAT; n = 6, white bars). Plasma heparin concentrations are expressed as mean AE standard error of means, ns indicates non-significantly different P values (P > 0.05), while * and *** indicate values significantly different (P < 0.05 and P < 0.001, respectively).
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heparin clearance in the model. Thus 30 min after antidote injection, only the group of rats treated with riAT exhibited significantly reduced plasma heparin activity (1.4 AE 0.5 u/ ml, P = 0.042) compared to the PBS group, whereas, in the group treated with protamine, mean plasma heparin concentration (4.5 AE 1.7 u/ml, P = 0.086) was not significantly different to the control. To assess residual heparin activity in plasma samples, a chromogenic assay would have been more specific than the aPTT assay. Unfortunately, in some cases, the CPB procedure induced haemolysis and haemoglobin release in plasma interfered with absorbance reading, independently of the rat group considered. This precluded the use of a chromogenic assay in 28% of the plasma samples. However, comparable results were found when heparinaemia was determined with an anti-factor Xa chromogenic assay or with the aPTT assay (data not shown). Taken together, these results indicate that riAT is a potent antidote to heparin after CPB procedures, reversing the anticoagulant activity, with at least the same efficiency.
Absence of adverse effecst of riAT on haemodynamic parameters and histamine release
Our rat model of CPB was set up to explore the phase of anticoagulant reversion after CPB and was found appropriate for demonstrating protamine adverse reactions. To test whether riAT may safely replace protamine to neutralize heparin after CPB, the impact of riAT injection on MAP, HR and histamine plasma level was evaluated in this model.
While protamine induced a transient drop in MAP (from 77.3 AE 0.8 mmHg to 68.8 AE 1.2 mmHg, P < 0.0001) and HR (from 338 AE 11 bpm to 283 AE 10 bpm, P = 0.0003) just after administration, riAT perfusion had no significant effect on MAP or HR (Fig 2) . Indeed, before and after riAT perfusion, both MAP (73.8 AE 1.9 mmHg, and 72.8 AE 1.4 mmHg, P = 0.6344) and HR (331 AE 7 ppm, and 326 AE 10 ppm, P = 0.8106) remained constant (Fig 2) . Furthermore, the mean values recorded in the group of rats treated with riAT remained comparable to those measured in the group of rats treated with PBS over the period post-CPB (P > 0.05).
In addition to its effect on haemodynamic parameters, protamine was reported to be responsible for histamine release ). In our model, an abnormally high plasma histamine concentration was observed after protamine perfusion (44 AE 7 ng/ml) (Fig 3) . Contrary to what was observed after treatment with protamine, the mean plasma level of histamine in the group of rats treated with riAT remained low and comparable to that measured in the control PBS group (7.5 AE 1.2 ng/ml in riAT group vs. 9.2 AE 1.7 ng/ml in PBS group, P = 0.82), indicating that riAT had no impact on histamine release (Fig 3) .
Discussion
The present study analysed the side effects and benefits of anticoagulant reversal after CPB procedure in a rat model. The model was validated with protamine, which significantly decreased heparin anticoagulant activity at the end of heart rate (HR), expressed in beats per minute (bpm) were recorded for 60 min after CPB. Phosphate-buffered saline (placebo; black squares), protamine (grey squares) or recombinant inactive antithrombin (riAT; white squares) was perfused over a period of 5 min immediately after interruption of CPB. Values are expressed as mean AE standard error of means, ** indicate values significantly different (P < 0.01) from the control (placebo) group. extracorporeal circulation, and was then used to compare riAT to protamine for its efficacy in reversing heparin anticoagulant activity. riAT presents none of the haemodynamic and biological side effects of protamine while behaving as a potent antidote of heparin, and could therefore represent a safer alternative to protamine in the anticoagulant-reversion protocol of extracorporeal circulation procedures.
A previous study, compared riAT and protamine in vitro, for their antidote effectiveness and their impact on human plasma coagulability in a thrombin generation assay (Bourti et al, 2016) . riAT had already been found to be as potent as protamine at reversing heparin, but, contrary to protamine, which exhibited intrinsic anticoagulant activity, riAT was totally devoid of any adverse procoagulant or anticoagulant activity on its own (Bourti et al, 2016) . Indeed, a recent study reported that a protamine-to-heparin ratio of 1.3 compared to 0.8 is associated with increased postoperative blood loss in cardiac surgery, highlighting the difficulty to manage protamine reversion (Meesters et al, 2016) . Furthermore, the half-life of riAT is expected to be longer than that of protamine (Butterworth et al, 2002) . These two parameters may explain why only the riAT treated group, and not the protamine group, still exhibited significantly lower anticoagulant activity 30 min after antidote administration compared to the placebo group.
To date, the use of protamine to neutralize heparin after CPB remains the standard reference, but this strategy may have some limitations due to rare but severe complications associated with protamine administration. The most common side effects of protamine are haemodynamic instability and anaphylaxis and therefore many studies were undertaken to develop safer alternatives to protamine (Horrow, 1985) . In our model, we could demonstrate the most common complications associated with protamine administration: hypotension and histamine release. These effects are related to the cationic nature of protamine peptide . Several heparin antagonists in development, including Ciraparantag (PER977) (Ansell et al, 2016) , PM102 (Cushing et al, 2010) or the universal heparin reversal agent (UHRA) (Shenoi et al, 2014) , a synthetic polymer presenting cationic heparin binding groups, share a nonspecific mechanism of action based on charge interaction, similarly to protamine. A main asset of riAT compared to these antidotes lies in its specificity, as demonstrated here by the observation that, compared to protamine, no hypotension or histamine release could be evidenced upon riAT administration. Among specific antidotes, andexanet alpha is a specific reversal agent for FXa inhibitors, including fondaparinux (Lu et al, 2013) . However, it has no inhibitory effects towards anti-IIa activity of heparins, precluding a complete neutralization of UFH during CPB. Platelet factor 4 (PF4), released from a-granules of activated platelets, tightly binds heparin and specifically neutralizes its anticoagulant activity. PF4 was found to be as efficient as protamine in reversing heparin after CPB without short-term adverse events in a small case series (Demma & Levy, 2012) . However, a potential drawback to the use of PF4 lies in its involvement in the pathogenesis of heparininduced thrombocytopenia (Rauova et al, 2006) .
Alternatively, other strategies propose to substitute heparin with other anticoagulants in combination with specific reversal agents. REG1 or Pegnivacogin, a RNA aptamer inhibitor of FIXa, and its reversal agent (anivamersens) were evaluated in a baboon model of CPB, but unfortunately failed to induce sufficient anticoagulation despite high FIXa inhibition, leading to thrombi formation in the bypass cannulation and kidney cortical infarcts (Bel et al, 2016) . Another interesting new anticoagulant-reversal agent in development is EP217609. EP217609 is a parenteral antithrombotic compound, combining, in one molecule, an indirect anti-factor Xa inhibitor and a direct thrombin active site inhibitor associated with a biotin moiety that can be neutralized by avidin (Olson et al, 2012) . This molecule was recently evaluated in humans (Gueret et al, 2016) . However, no data are currently available in a CPB model.
As previously demonstrated, riAT acts with comparable efficacy toward all AT-dependent anticoagulants, such as UFH and LMWH, but also fondaparinux (Bianchini et al, 2011; Bourti et al, 2016) . This may open new perspectives for the use of fondaparinux as the anticoagulant in procedures requiring short term coagulation, and the fondaparinux/riAT pair may provide an alternative to the heparin/ protamine pair when clinically needed.
In conclusion, this study shows that riAT is as potent as protamine for reversing heparin anticoagulant activity after CPB in rats and may represent an advantage over protamine because none of the adverse events associated with protamine, particularly haemodynamic instability and release of histamine, were observed with riAT in an anticoagulant/reversal protocol post-CPB. Although promising, riAT remains to be evaluated for its immunogenicity and safety before it can be considered for therapeutic indication in humans.
